The content published in Cureus is the result of clinical experience and/or research by independent individuals or organizations. Cureus is not responsible for the scientific accuracy or reliability of data or conclusions published herein. All content published within Cureus is intended only for educational, research and reference purposes. Additionally, articles published within Cureus should not be deemed a suitable substitute for the advice of a qualified health care professional. Do not disregard or avoid professional medical advice due to content published within Cureus.

Introduction
============

Pituitary tumors are a heterogeneous collection of neoplasms that arise from the pituitary gland. They are the third most common intracranial tumor, with an estimated overall prevalence of 16.7% \[[@REF1]-[@REF2]\]. Surgical resection remains a mainstay treatment for functioning pituitary tumors and is indicated as first-line treatment in many instances, particularly when symptomatic mass-effect or visual deficits are present \[[@REF3]-[@REF5]\]. Studies on the efficacy of surgical resection suggest that surgery is able to successfully achieve hormonal resolution in upwards of 80% of tumor subtypes, with relatively low rates of complication and mortality \[[@REF6]\]. Given the frequency of pituitary tumors, their associated morbidity, and the benefits from surgical intervention, there exists substantial interest in determining factors that influence early detection, management, and survival outcomes.

Socioeconomic status (SES) is a composite measure that includes variables pertaining to occupation, education, and income. SES has been found to be associated with disparities in incidence, treatment received (including radiation therapy, surgical resection, and adjuvant therapy), and survival outcomes for various cancers including lung, prostrate, breast, and cervix cancers \[[@REF7]-[@REF8]\]. SES also has also been associated with overall survival and odds of receiving treatment for intracranial tumors \[[@REF9]-[@REF10]\].

Race has also been found to be a predictor for variation in neuro-oncological care. In a study of 76,436 cases of tumor biopsy or resection, African Americans and Hispanics had disproportionately worse access to high-quality neuro-oncologic care over time compared with white patients \[[@REF11]\]. Furthermore, a national study of over 84,000 patients showed that black patients were 38% less likely to receive surgery when compared to white patients, and black patients from high SES had lower surgical rates than white and Hispanic patients from low SES backgrounds \[[@REF12]\]. Similar patterns have been found for lung, esophageal, and pancreatic cancers \[[@REF13]\]. Limitations in access to quality care, as well as differences in patient engagement during provider selection, have previously been suggested to contribute to patterns of race-specific differences \[[@REF14]\].

Currently, few studies have investigated racial and socioeconomic determinants of pituitary tumor outcomes. Prior analysis using the Surveillance, Epidemiology, and End Results (SEER) program database from at the National Cancer Institute has uncovered associations between pituitary adenoma incidence rates and age, gender, and race \[[@REF15]\]. In another national study, SES and race were associated with differing odds of admittance to high-volume centers for pituitary adenoma patients undergoing trans-sphenoidal surgery \[[@REF16]\]. In a single-center study, increased length of stay following trans-sphenoidal resection of pituitary adenoma was associated with lower SES \[[@REF17]\]. These studies, however, utilized varying matrices of SES, employed single-center designs, and/or did not investigate rates of treatment received. Using a uniform and comprehensive index of SES developed by Yost et al., this national retrospective study aims to determine whether SES and race are determinants of surgical intervention and survival probabilities of patients with pituitary tumors \[[@REF18]\].

Materials and methods
=====================

Patients diagnosed with pituitary tumors between 2003 and 2012 were identified using a custom database consisting of 17 registries from the SEER program database of the National Cancer Institute. Study-eligible patients included those who had primary pituitary tumors, had a known age of diagnosis and were actively followed. The resulting cohort included approximately 28% of the patients in the United States with the diagnosis of pituitary tumor. Patient death information was gathered by the SEER program from the National Death Index, as well as state, local, and institutional records. Patient follow-up time was measured in months; patients were followed from the time of diagnosis (when they were reported to the SEER registry) to 60 months, until death, loss to follow up, or the study cutoff date (December 2012), whichever occurred first. Records from Alaska and Louisiana were excluded on the basis of incompleteness. All data from this database are de-identified, and thus this study is exempt from IRB approval in accordance with the Health Insurance Portability and Accountability Act of 1996.

A diagnosis of pituitary tumor was specified using the SEER variables "Histology record -- Brain groupings" (for tumor type) and "Primary Site" (for tumor location). For the "Histology recode---brain groupings" variable, the value 'Pituitary' was used to specify tumor type. For the tumor site variable "Primary Site", the value 'C75.1 -- Pituitary Gland' was used. Additionally, the World Health Organization (WHO) grading criteria (Grades 1-4 and unknown), as adopted by the SEER classification system, was used to categorize patients according to tumor grade. SES was calculated using an index developed by Yost et al. \[[@REF18]\]. The index scores patients based on national census-tract information at the time of entry into the registry, which includes SES markers such as education level, median income, median home value, median rent, poverty level, and employment status. The scores are then divided into tertiles (T1-T3) and quintiles (Q1-Q5). T1 and Q1 denote the lowest socioeconomic stratum, while T3 and Q5 denote the highest, and reflect the patient SES compared to a national population. Treatments received by patients were treated as binary variables, and included surgery, radiation, and radiation with surgery. These treatment categories were, however, not exclusive. Race was categorized as Caucasian or non-Caucasian based on self-reported data in the SEER database.

The odds of receiving treatment based on SES and race were determined using multivariable logistic regression. Survival probabilities, based on SES, race, and treatment modality, were analyzed using Cox proportional hazards model. All results were adjusted for age at diagnosis, sex, and tumor grade. P-values of less than 0.05 were considered significant. Data were analyzed using SAS v9.4 (SAS Institute Inc., Cary, NC, USA).

Results
=======

The study identified 25,802 patients diagnosed with pituitary tumors, with an average age at diagnosis of 50.18 years; 55.2% of participants in the sample were female, and 71.7% of patients in this cohort were Caucasian. When divided into SES tertiles, 32.6% of patients were in T1, and 19.2% patients were in Q1 when divided into quintiles. 45.2% of patients in this cohort received surgery, 4.7% received radiation, and 3.7% received radiation combined with surgery. Median follow-up time was 42 months (Table [1](#TAB1){ref-type="table"}).

###### Study Population Demographics

N = number of participants; SEM = standard error of the mean.

  ------------------------------------ -----------------
  Study Population Demographics        
  N                                    25,802
  Sex, N \[%\]                          
  Male                                 11,550 \[44.8\]
  Female                               14,252 \[55.2\]
  Race, N \[%\]                         
  Caucasian                            18,508 \[71.7\]
  Non-Caucasian                        6,818 \[26.4\]
  Unknown                              476 \[1.85\]
  Mean age at diagnosis ± SEM, years   50.18 ± 0.11
  Tertile distribution, N \[%\]         
  Tertile 1                            8,410 \[32.6\]
  Tertile 2                            8,643 \[33.5\]
  Tertile 3                            8,749 \[33.9\]
  Quintile distribution, N \[%\]        
  Quintile 1                           4,945 \[19.2\]
  Quintile 2                           5,196 \[20.1\]
  Quintile 3                           5,197 \[20.1\]
  Quintile 4                           5,168 \[20.0\]
  Quintile 5                           5,296 \[20.5\]
  Treatment, N \[%\]                    
  Surgery                              9,872 \[45.2\]
  Radiation                            1,210 \[4.73\]
  Radiation with Surgery               973 \[3.77\]
  Median Follow-up, Months             42
  Dead at Study Cutoff, N \[%\]        9 \[0.03\]
  Lost to Follow-up, N \[%\]           17,257 \[66.9\]
  ------------------------------------ -----------------

Effect of SES on treatment received

After adjusting for age at diagnosis, sex, race, and tumor grade, high SES tertile (odds ratio (OR)=1.095) and quintile (OR=1.052) were found to be associated with higher odds of receiving surgery (p\<0.0001) (Table [2](#TAB2){ref-type="table"}). There were no significant associations between SES and receiving radiation or radiation with surgery. The distributions of patients who received surgery, radiation, or radiation with surgery across SES strata are summarized in Tables [3A](#TAB3){ref-type="table"}-[3B](#TAB3){ref-type="table"} for SES tertiles and quintiles, respectively.

###### Effect of High SES on Treatment Received

OR = odds ratio; SES = socioeconomic status.

  --------------------------------------------------------------------------- ------- ------------------------- ----------
                                                                              OR^a^   95% Confidence Interval   p-value
  Treatment for SES Tertiles                                                                                     
  Surgery                                                                     1.095   (1.059 -- 1.132)          \<0.0001
  Radiation                                                                   0.948   (0.883 -- 1.019)          0.1493
  Radiation with Surgery                                                      0.968   (0.894 -- 1.048)          0.4214
  Treatment for SES Quintiles                                                                                    
  Surgery                                                                     1.052   (1.031 -- 1.072)          \<0.0001
  Radiation                                                                   0.962   (0.923 -- 1.003)          0.0719
  Radiation with Surgery                                                      0.975   (0.931 -- 1.021)          0.2746
  Reference = Lowest SES (lowest 3rd tertile or 5th quintile, respectively)                                     
  ^a^Adjusted for Age at Diagnosis, Sex, Race, and Tumor Grade                                                  
  --------------------------------------------------------------------------- ------- ------------------------- ----------

###### Treatment Received by SES Tertile (A) and Quintile (B)

N = number of participants; SES = socioeconomic status. T1-T3 are \'Tertiles\' and \'Quintiles\' are Q1-Q5.

  ------------------------------------------------ ---------------- ---------------- ----------------
  A. Treatment Received (N \[%\]) by SES Tertile                                     
                                                   T1               T2               T3
  Surgery                                          3,068 \[31.1\]   3,286 \[33.3\]   3,518 \[35.6\]
  Radiation                                        409 \[33.8\]     403 \[33.3\]     398 \[32.9\]
  Radiation with Surgery                           323 \[33.2\]     325 \[33.4\]     325 \[33.4\]
  ------------------------------------------------ ---------------- ---------------- ----------------

  ------------------------------------------------- ---------------- ---------------- ---------------- ---------------- ----------------
  B. Treatment Received (N \[%\]) by SES Quintile                                                                       
                                                    Q1               Q2               Q3               Q4               Q5
  Surgery                                           1,812 \[18.4\]   1,934 \[19.6\]   1,976 \[20.0\]   1,954 \[19.8\]   2,196 \[22.2\]
  Radiation                                         232 \[19.2\]     268 \[22.2\]     247 \[20.4\]     224 \[18.5\]     239 \[19.8\]
  Radiation with Surgery                            180 \[18.5\]     217 \[22.3\]     197 \[20.3\]     186 \[19.1\]     193 \[19.8\]
  ------------------------------------------------- ---------------- ---------------- ---------------- ---------------- ----------------

Effect of race on treatment received

After adjusting for age at diagnosis, sex, socioeconomic status, and tumor grade, Caucasian patients were found to have higher odds of receiving surgery when compared to non-Caucasian patients (OR=1.064, p\<0.05). Race was not a significant predictor of receiving radiation therapy or radiation with surgery (Table [4](#TAB4){ref-type="table"}). The distribution of treatment received stratified by race is summarized in Table [5](#TAB5){ref-type="table"}.

###### Effect of Caucasian Race on Treatment Received

OR = odds ratio; SES = socioeconomic status.

  -------------------------------------------------------------- ------- ------------------------- ---------
                                                                 OR^a^   95% Confidence Interval   p-value
  Surgery                                                        1.064   (1.000 -- 1.133)          0.0488
  Radiation                                                      1.125   (0.982 -- 1.287)          0.0886
  Radiation with Surgery                                         1.107   (0.953 -- 1.285)          0.1846
  Reference = Non-Caucasian race                                                                   
  ^a^ Adjusted for Age at Diagnosis, Sex, SES, and Tumor Grade                                     
  -------------------------------------------------------------- ------- ------------------------- ---------

###### Treatment Received by Race

N = number of participants.

  ------------------------ -------------------- ------------------------
                           Caucasian, N \[%\]   Non-Caucasian, N \[%\]
  Surgery                  7,224 \[74.2\]       2,511 \[25.8\]
  Radiation                900 \[74.9\]         301 \[25.1\]
  Radiation with Surgery   725 \[74.9\]         243 \[25.1\]
  ------------------------ -------------------- ------------------------

Effect of SES and race on survival probability

There was no significant effect of race on survival probability when adjusted for age at diagnosis, sex, SES, and tumor grade (hazard ratio (HR)=3.014, p\>0.05). Neither high SES tertile (HR=0.786) nor quintile (HR=0.799) were significant predictors of survival probability when adjusted for age at diagnosis, sex, race, and tumor grade (p\>0.05). Furthermore, neither surgery (HR=0.161) nor radiation with surgery (HR=0.358) were significant predictors of survival when adjusted for age of diagnosis, sex, race, and tumor grade (p\>0.05).

Discussion
==========

This national study of 25,802 patients diagnosed with pituitary tumors investigated the role of SES and race on treatment received and overall survival. Our analysis found associations between high SES tertile/quintile and increased likelihood of receiving surgery, after adjusting for age at diagnosis, sex, race, and tumor grade. This finding is consistent with associations found in previous analyses which examined pituitary disease procedures at high-volume centers \[[@REF16]\]. Given the multitude of factors that influence socioeconomic status, various elements may contribute to disparities seen in receiving treatment. Access to surgery may be influenced in part by financial determinants such as household income, insurance status, and regional coverage, which have been shown to impact access to surgical treatment for various cancer types \[[@REF19]-[@REF21]\]. Moreover, geographic characteristics, such as hospital volume and local referral patterns, may influence treatment selection by influencing both physical access to care as well as the quality of care. Further studies are required to explore the role of specific SES factors that impact treatment.

Caucasian race was also found to be associated with higher odds of receiving surgery, after adjusting for age at diagnosis, sex, SES, and tumor grade. Results from several nationwide studies confirm this finding, having demonstrated that the Caucasian race is an independent predictor for receiving surgical treatment for pituitary tumors \[[@REF13],[@REF16],[@REF20],[@REF22]\]. These findings may be the result of multiple factors. First, there may be an inherent difference in pituitary tumor incidence across races. A previous analysis by McDowell et al. using the SEER database demonstrated that incidence rates of pituitary tumors varied according to age and race \[[@REF15]\]. They found that age-adjusted incidence rates from 2004-2007 were significantly higher for African-Americans (4.4 per 100,000) compared to American Indians/Alaskan Natives (1.9 per 100,000), Asians/Pacific Islanders (2.3 per 100,000), and Caucasians (2.5 per 100,000) \[[@REF15]\].

The possibility that Caucasian patients are predisposed to particular subtypes of pituitary tumors may also explain their increased likelihood of requiring and thus receiving surgery, for example, for non-prolactinomas, or more rapidly-growing tumors that cause visual or endocrinological abnormalities \[[@REF15]\]. There has been relatively little investigation thus far on the extent to which pituitary hormonal characteristics vary according to geography and race; however, a study by Cimpean et al. found significantly different immunohistochemical and hormonal profiles in patients with pituitary adenomas in two separate European countries \[[@REF23]\]. Their results may lend support to the concept of specific epidemiological factors affecting the biological characteristics of pituitary tumors.

Another possible explanation for the effect of race on treatment stems from evidence demonstrating the disproportionality in pituitary tumor diagnosis as incidental findings across patient populations \[[@REF15]\]. When diagnosed as incidental findings, tumors may be clinically insignificant and therefore, not require surgical management. For example, African American patients, who experience higher rates of stroke compared to Caucasians, would necessarily undergo higher rates of brain imaging, and consequently may have higher rates of incidental diagnoses of pituitary tumors on imaging. Thus, due to these inherent differences in imaging rates, non-white patients may be more likely to have asymptomatic pituitary tumors found incidentally, and less likely to undergo surgery \[[@REF15]\].

Finally, these findings may be also explained by the differences in healthcare accessibility for various ethnicities. Prior analysis of national Medicare data found that African-American patients are overwhelmingly seen at a smaller concentration of hospitals, suggesting racial differences in access to care \[[@REF24]\]. Furthermore, Liu et al. reported in an analysis of surgical procedures across hospitals in California that non-white patients have a significantly reduced likelihood of being seen at high volume hospitals relative to white patients \[[@REF25]\]. Thus, the relatively limited access to healthcare for non-white patients may underlie the racial variances observed in this study. It is also possible that our findings were influenced by additional systemic biases previously observed for physician decision-making and management between white and non-white patients \[[@REF26]\].

Surgery remains a common treatment for pituitary tumors, and inability to receive surgery can contribute significantly to morbidity. Surgery is typically indicated for visual field loss, excess hormonal production, and tumor progression in pituitary tumors other than prolactinomas. For prolactinomas, dopamine agonists are commonly used as adjuvant therapy; however, surgery remains an effective treatment option in certain clinical scenarios including visual field loss, and intolerance or resistance to dopamine agonists \[[@REF27]\]. The pattern of treatment modality utilization found in this study is similar to those observed in other national-level reports. Olsson et al. found, in a cohort of 2,795 non-functional pituitary adenoma patients, a 53% rate of surgery alone \[[@REF28]\]. Similarly, Lesén et al. demonstrated a frequency of 60% for surgery as the first-line treatment in a Sweden-wide cohort of 358 acromegaly patients \[[@REF29]\]. Consequently, socioeconomic and racial effects of receiving surgical treatment hold significant implications for the quality of life of patients with pituitary tumors. In the absence of surgical treatment, symptomatic patients may continue to experience the debilitating conditions that result from these tumors, such as Cushing's disease and acromegaly, or loss of peripheral vision that results from mass effects. However, the significant morbidity associated with these conditions is not reflected in the outcome of overall survival as measured in this study.

This study found no association between SES or race and receiving radiation or radiation with surgery. In addition, no significant racial, socioeconomic, or treatment-specific associations with survival probability in pituitary tumors were found, likely due to the relatively low mortality of these tumors. In the case of surgically-managed pituitary tumors, mortality across all subtypes ranges from 1%-8%, with an overall mortality of 1.6% \[[@REF30]\]. Detection of subtle differences in mortality may thus require a significantly longer time period than the five-year window used in this study. Future studies assessing specific symptoms (e.g., visual loss), disability, hormonal cure, and other quality of life metrics may allow further insight into outcome variation.

Limitations of this study include restrictions associated with treatment and outcome variables of the database, as well as lack of subcategory tumor-type classifications. The SEER database does not include information regarding medical management of pituitary tumors and the use of hormonal replacement; nor does it contain information about the use of chemotherapy or dopamine agonists. The database also does not parse out subcategories and histological variants of pituitary masses. This study also does not stratify non-Caucasian patients into different ethnicities, as it was designed to detect significant differences between two sufficiently powered patient cohorts. There may be, however, further heterogeneity in treatment receipt based on race, which may be investigated in a future study with a larger number of non-Caucasian patients.

Future work which examines the role of specific SES factors (e.g., financial and geographic determinants) and subcategories of race may further elucidate the causes of trends identified in this study. In addition, prospective studies designed to further stratify patients based on tumor genetics and histopathology prior to outcomes analysis may uncover factors that explain disparities in access and quality of care for pituitary tumors. Ongoing public health research within this domain can help answer questions that may lead to the development of targeted interventions for improved access to pituitary cancer treatment.

Conclusions
===========

In conclusion, this national study of 25,802 patients identifies socioeconomic status and race as significant predictors of receiving surgery for pituitary tumors. These findings contribute to the growing body of literature analyzing demographic influences on cancer outcome. Further investigation is required to understand possible reasons for these associations, to help ensure optimal care across the entire population.
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